RUA BIOSCIENCE LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.049 NZD | +2.08% |
|
0.00% | -59.17% |
| 07/05 | Rua Bioscience Extends Distribution Agreement with Germany's Nimbus Health | MT |
| 07/05 | Rua Bioscience Limited Extends Agreement with Nimbus Health in Germany | CI |
Valuation
| Fiscal Period: Juni | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 57.51 | 49.46 | 24.35 |
| Enterprise Value (EV) 1 | 42.06 | 40.35 | 19.91 |
| P/E ratio | -11.8 x | -5.5 x | -3.85 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | 76.7 x | 36.4 x |
| EV / Revenue | - | 62.5 x | 29.8 x |
| EV / EBITDA | -6.96 x | -5.81 x | -1.74 x |
| EV / FCF | -1,07,02,357 x | -2,63,69,548 x | -19,11,568 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 1.99 x | 2.04 x | 1.21 x |
| Nbr of stocks (in thousands) | 1,40,263 | 1,49,879 | 1,58,136 |
| Reference price 2 | 0.4100 | 0.3300 | 0.1540 |
| Announcement Date | 30/08/21 | 29/08/22 | 29/08/23 |
1NZD in Million2NZD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 0.2219 | 0.5916 | - | 0.6451 | 0.6685 |
| EBITDA 1 | -2.003 | -3.723 | -6.045 | -6.941 | -11.42 |
| EBIT 1 | -2.036 | -3.873 | -6.641 | -7.584 | -12.01 |
| Operating Margin | -917.31% | -654.65% | - | -1,175.69% | -1,795.96% |
| Earnings before Tax (EBT) 1 | -1.982 | -3.718 | -6.174 | -7.486 | -5.959 |
| Net income 1 | -1.968 | -2.9 | -4.418 | -8.636 | -5.959 |
| Net margin | -886.92% | -490.23% | - | -1,338.73% | -891.46% |
| EPS 2 | -0.0376 | -0.0341 | -0.0347 | -0.0600 | -0.0400 |
| Free Cash Flow | - | -6.796 | -3.93 | -1.53 | -10.41 |
| FCF margin | - | -1,148.79% | - | -237.17% | -1,557.78% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 28/08/20 | 28/08/20 | 30/08/21 | 29/08/22 | 29/08/23 |
1NZD in Million2NZD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 5.96 | 3.59 | 15.4 | 9.11 | 4.45 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | -6.8 | -3.93 | -1.53 | -10.4 |
| ROE (net income / shareholders' equity) | - | -23.3% | -20.4% | -32.6% | -26.9% |
| ROA (Net income/ Total Assets) | - | -18% | -17.8% | -14.7% | -27.5% |
| Assets 1 | - | 16.11 | 24.79 | 58.69 | 21.65 |
| Book Value Per Share 2 | 0.2000 | 0.1400 | 0.2100 | 0.1600 | 0.1300 |
| Cash Flow per Share 2 | 0.0800 | 0.0400 | 0.0200 | 0.0100 | 0.0200 |
| Capex 1 | 0.46 | 5.02 | 1.4 | 0.4 | 0.07 |
| Capex / Sales | 205.07% | 848.7% | - | 62.02% | 11.04% |
| Announcement Date | 28/08/20 | 28/08/20 | 30/08/21 | 29/08/22 | 29/08/23 |
1NZD in Million2NZD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -59.17% | 4.77M | |
| +28.10% | 5.6B | |
| -33.42% | 3.53B | |
| -3.74% | 3.03B | |
| -26.09% | 2.58B | |
| -10.93% | 2.31B | |
| +41.50% | 1.86B | |
| +40.90% | 1.45B | |
| +46.67% | 1.41B | |
| -27.59% | 1.27B |
- Stock Market
- Equities
- RUA Stock
- Financials Rua Bioscience Limited
